Bessemer Group Inc. lessened its position in National Research Co. (NASDAQ:NRCIA) by 7.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,233 shares of the business services provider’s stock after selling 3,518 shares during the period. Bessemer Group Inc. owned about 0.17% of National Research worth $1,538,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Schwab Charles Investment Management Inc. boosted its holdings in shares of National Research by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 30,453 shares of the business services provider’s stock worth $820,000 after buying an additional 190 shares during the period. Alliancebernstein L.P. boosted its holdings in shares of National Research by 5.1% during the 2nd quarter. Alliancebernstein L.P. now owns 12,369 shares of the business services provider’s stock worth $333,000 after buying an additional 600 shares during the period. Strs Ohio boosted its holdings in shares of National Research by 12.7% during the 4th quarter. Strs Ohio now owns 20,400 shares of the business services provider’s stock worth $760,000 after buying an additional 2,300 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of National Research by 75.2% during the 3rd quarter. Wells Fargo & Company MN now owns 9,450 shares of the business services provider’s stock worth $356,000 after buying an additional 4,056 shares during the period. Finally, Citigroup Inc. boosted its holdings in shares of National Research by 120.2% during the 2nd quarter. Citigroup Inc. now owns 8,299 shares of the business services provider’s stock worth $224,000 after buying an additional 4,531 shares during the period. 25.40% of the stock is owned by institutional investors.
Several analysts recently commented on the stock. Zacks Investment Research raised shares of National Research from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 10th. BidaskClub raised shares of National Research from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th.
National Research Co. (NRCIA) opened at $35.30 on Wednesday. The company has a market cap of $856.87, a P/E ratio of 70.60 and a beta of 1.54. National Research Co. has a 12-month low of $16.90 and a 12-month high of $41.99.
In related news, CEO Michael D. Hays sold 1,602,399 shares of National Research stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $39.03, for a total transaction of $62,541,632.97. Following the sale, the chief executive officer now directly owns 5,261,410 shares of the company’s stock, valued at approximately $205,352,832.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 37.54% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/14/national-research-co-nrcia-stake-decreased-by-bessemer-group-inc.html.
National Research Profile
National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers, payers and other healthcare organizations. The Company operates through six segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Connect.
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.